NPI: 1922586254 · MIAMI, FL 33165 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 07/30/2018
Authorized official WINSTEL, JOHN controls 20+ related entities in our dataset. Read more
| Authorized Official | WINSTEL, JOHN (CHIEF ACCOUNTING OFFICER) |
| NPI Enumeration Date | 07/30/2018 |
Other providers sharing the same authorized official: WINSTEL, JOHN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 1,708 | $607K |
| 2019 | 17,535 | $2.98M |
| 2020 | 17,281 | $2.41M |
| 2021 | 11,664 | $540K |
| 2022 | 3,400 | $277K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 15,734 | 979 | $2.31M |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 14,888 | 595 | $1.78M |
| J1270 | Injection, doxercalciferol, 1 mcg | 9,806 | 564 | $1.36M |
| A4657 | Syringe, with or without needle, each | 2,772 | 688 | $342K |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 1,332 | 402 | $220K |
| J1756 | Injection, iron sucrose, 1 mg | 2,791 | 352 | $169K |
| 85041 | 799 | 451 | $117K | |
| 85048 | 710 | 403 | $110K | |
| 82728 | 694 | 361 | $104K | |
| 83970 | 580 | 312 | $93K | |
| 83550 | 672 | 351 | $93K | |
| 83540 | 660 | 350 | $93K | |
| J0882 | Injection, darbepoetin alfa, 1 microgram (for esrd on dialysis) | 29 | 12 | $12K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 73 | 42 | $10K |
| 82108 | 48 | 28 | $9K |